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1. INTRODUCTION {#cam41553-sec-0001}
===============

Pancreatic cancer has been the fourth leading cause of cancer mortality in the USA with a dismal 5‐year survival rate of 8%.[1](#cam41553-bib-0001){ref-type="ref"} The latest findings also showed that in contrast to the declining trends for the 4 major cancers, the mortality of pancreatic cancer continues to increase slightly (by 0.3% per year) in men but have leveled off in women.[2](#cam41553-bib-0002){ref-type="ref"} Similar trends were found in China with increasing incidences and cancer deaths.[3](#cam41553-bib-0003){ref-type="ref"}

Due to its insidious symptoms and unsuccessful population‐based screenings, majority of patients had locally advanced pancreatic cancer (LAPC) at the initial diagnosis. In spite of potential survival benefit over radiotherapy or chemotherapy alone produced by concurrent chemoradiotherapy,[4](#cam41553-bib-0004){ref-type="ref"}, [5](#cam41553-bib-0005){ref-type="ref"}, [6](#cam41553-bib-0006){ref-type="ref"}, [7](#cam41553-bib-0007){ref-type="ref"}, [8](#cam41553-bib-0008){ref-type="ref"} contrary conclusions were also clarified.[9](#cam41553-bib-0009){ref-type="ref"}, [10](#cam41553-bib-0010){ref-type="ref"}, [11](#cam41553-bib-0011){ref-type="ref"}, [12](#cam41553-bib-0012){ref-type="ref"}

As a result, there is no consensus on the optimal management of LAPC. Hence, chemotherapy or induction chemotherapy followed by chemoradiation or chemoradiation alone or enrollment of clinical trials was employed based on NCCN guidelines. While given the shortcomings of conventional radiotherapy, stereotactic body radiation therapy (SBRT) has been a promising option in pancreatic cancer due to its inherent advantages including high local dose conformation, precise target localization [13](#cam41553-bib-0013){ref-type="ref"} with motion compensation strategies [14](#cam41553-bib-0014){ref-type="ref"}, [15](#cam41553-bib-0015){ref-type="ref"} and quick dose fall‐off outside the tumor volume.[16](#cam41553-bib-0016){ref-type="ref"}, [17](#cam41553-bib-0017){ref-type="ref"}

Although chemotherapy and radiotherapy have played a pivotal role in the treatment of patients with LAPC, several controversial issues remain unresolved. Particularly, the best upfront combined regimens of different modalities as well as the optimal treatment strategy are still a matter of debate.

Therefore, in this study, we sought to evaluate impacts of different multimodality for LAPC on overall survival (OS) and progression‐free survival (PFS) and factors correlated with determinations of treatment strategies.

2. METHODS {#cam41553-sec-0002}
==========

The study was approved by the institutional review board of our hospital. Data were collected prospectively from 2012 to 2016. All patients were carefully assessed before treatment based on the medical records, imaging studies, histological examinations and laboratory tests. A prospective maintained pancreatic cancer database was used to identify consecutive patients who had LAPC and received SBRT between January 2012 and December 2016. Informed consents, including publication of details, of all patients were provided before treatment.

2.1. Eligibility {#cam41553-sec-0003}
----------------

All patients included in this study were LAPC. Patients were eligible for inclusion if meeting the following criteria: (1) biopsy‐proven and radiologically locally advanced pancreatic cancer, (2) ECOG performance status ≤2, (3) leukocyte count ≥3.5 × 10^9^/L, neutrophil count ≥1.5 × 10^9^/L, hemoglobin level ≥100 g/L, platelet count ≥100 × 10^9^/L and normal liver and kidney function, and (4) completion of a planned chemotherapy with 6 cycles.

Patients who had completed induction chemotherapy would receive PET‐CT to preclude metastasis. Those with metastasis were excluded from the study and received other treatment based on the multidisciplinary approach. Those without metastasis would receive SBRT thereafter.

2.2. Staging {#cam41553-sec-0004}
------------

Comprehensive clinical and radiographic staging, including chest computed tomography and abdominal computed tomography or magnetic resonance imaging scan and laboratory studies, was mandatory prior to treatment. Furthermore, pathological examinations with fine‐needle aspiration guided by endoscopic ultrasound were preferred for all patients. The most recent results of laboratory and imaging studies before initiation of treatment were utilized for analysis. Consensus regarding the definition of LAPC was provided by the multidisciplinary team based on NCCN guidelines.

2.3. Chemotherapy {#cam41553-sec-0005}
-----------------

Patients were required to receive gemcitabine and S‐1 in addition to SBRT. However, other palliative care would be given if patients were intolerant of chemotherapy. S‐1 was the prodrug of 5‐fluorouracil comprising of tegafur, gimeracil, and oteracil. It was proven that S‐1 was not inferior to gemcitabine in terms of overall survival rates and progression‐free survival rates with tolerable effects.[18](#cam41553-bib-0018){ref-type="ref"}, [19](#cam41553-bib-0019){ref-type="ref"}, [20](#cam41553-bib-0020){ref-type="ref"}, [21](#cam41553-bib-0021){ref-type="ref"} Patients were recommended to receive up to 6 months of chemotherapy. The interval between SBRT and chemotherapy was 2‐3 weeks. Intravenous administration of gemcitabine (1000 mg/m^2^) was initiated on days 1, 8, and 15 during each 4‐week cycle, which repeated for 6 cycles. S‐1 was orally given at a dose of 80 mg/m^2^ for 28 days followed by a 14‐day rest, which also continued for 6 cycles.

2.4. Treatment planning and delivery {#cam41553-sec-0006}
------------------------------------

The protocol of SBRT was similar to our previous studies.[22](#cam41553-bib-0022){ref-type="ref"}, [23](#cam41553-bib-0023){ref-type="ref"} SBRT was delivered *via* CyberKnife^®^ (Accuray Incorporated, Sunnyvale, CA), an image‐guided frameless stereotactic robotic radiosurgery system. All patients underwent endoscopic ultrasound‐guided implantation of 3‐5 gold fiducials within or adjacent to the pancreatic tumor. Patients underwent CT simulation supine in custom‐fit immobilization devices with intravenous contrast. Gross tumor volume (GTV) was delineated as a radiographically evident gross disease by contrast CT. Clinical target volume (CTV) encompassing areas of the potential subclinical disease spread was also designated. In most cases, the CTV equaled GTV. Planning target volume (PTV) included a 2‐5‐mm margin on GTV. When the tumor abutted critical organs, the expansion of PTV outside of CTV in this direction should be avoided. Therefore, the margin expansion was allowed to be nonuniform. At least ninety percent of PTV should be covered by the prescription dose. Normal tissue constraints were referred to the American Association of Physicists in Medicine guidelines in TG‐101.[24](#cam41553-bib-0024){ref-type="ref"}

2.5. Follow‐up {#cam41553-sec-0007}
--------------

Patients were evaluated initially every 2‐3 months within 1 year after treatment and later every 4‐6 months with CT or MRI scans, physical examinations, and CA19‐9 for a planned follow‐up of 5 years. Any other examinations prompted by new‐onset symptoms or at the physician's discretions were also used to record events.

2.6. Definitions and collection of data {#cam41553-sec-0008}
---------------------------------------

Disease recurrence was based on review of the medical records and imaging studies, including newly found mass or growth of the primary lesion. A new low‐density mass on CT or MRI consistent with recurrent local, regional, or metastatic disease was considered as such, and tumor biopsy was rarely performed.[25](#cam41553-bib-0025){ref-type="ref"} Differential diagnosis of tumor necrosis induced by SBRT, which may be mistaken for progression, would be performed by three radiologists based on MRI scan. OS was determined from the date of histologic diagnosis to death. The definition of PFS was from the date of histologic diagnosis to the date of the first recurrence. Tumor response was judged by RECIST Criteria version 1.1. Adverse effects caused by chemotherapy were reviewed and collected by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Radiation‐induced acute toxicities were determined by "Acute radiation morbidity scoring criteria" from Radiation Therapy Oncology Group. While late toxicities were evaluated by "Late radiation morbidity scoring schema" from Radiation Therapy Oncology Group/European Organization for Research on the Treatment of Cancer.[26](#cam41553-bib-0026){ref-type="ref"}

A systemic inflammation response index (SIRI) has been proven predictive of prognosis of patients with pancreatic cancer.[27](#cam41553-bib-0027){ref-type="ref"} The value was calculated as:$$\begin{array}{cl}
\text{SIRI} & = \\
 & {\frac{\text{total\ neutrophil\ count}\,{(/\text{mm}^{3})}\, \times \,\text{total\ monocyte\ count}\,{(/\text{mm}^{3})}}{\text{total\ lymphocyte\ count}\,(/\text{mm}^{3})}.} \\
\end{array}$$

The prognostic nutritional index (PNI) represented patient's nutritional status, which was the known predictor of the survival of pancreatic cancer.[28](#cam41553-bib-0028){ref-type="ref"}, [29](#cam41553-bib-0029){ref-type="ref"} The formula was as follows: PNI = 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm^3^). Charlson age‐comorbidity index (CACI) was originally designed to classify prognostic comorbidity.[30](#cam41553-bib-0030){ref-type="ref"} It was clarified that CACI was associated with prognosis of patients with pancreatic cancer.[31](#cam41553-bib-0031){ref-type="ref"} Pain was quantified by visual analog scale (VAS).

The recommended upper limit of normal for CA19‐9 is 37 U/mL.[32](#cam41553-bib-0032){ref-type="ref"} Additionally, a phase I/II study of *nab‐*Paclitaxel + Gemcitabine that preceded advanced pancreatic cancer demonstrated a significant correlation between decreases in CA19‐9 levels of ≥50% vs \<50% from baseline and improved survival.[33](#cam41553-bib-0033){ref-type="ref"} Therefore, CA19‐9 response was defined as the level of CA19‐9 decrease by 50% from baseline levels of ≥74 U/mL. Hence, three CA19‐9 groups were formed for univariate analysis: CA19‐9 levels ≥74 U/mLwith response vs CA19‐9 levels ≥74 U/mL with no response (including CA19‐9 levels within the normal range before SBRT while increased after SBRT) vs CA19‐9 levels \<74 U/mL (before SBRT and during follow‐up). The nadir value of CA19‐9 level during the follow‐up was utilized for the estimation of CA19‐9 decrease. Additionally, it was shown that CA19‐9 level less than 200 U/mL was associated with major response for localized pancreatic cancer treated with preoperative therapy.[34](#cam41553-bib-0034){ref-type="ref"} Therefore, the serum level of CA19‐9 before SBRT was stratified as: \<200 and ≥200 U/mL.

The N stage (TNM staging) was based on the absence or presence of metastasis to the regional lymph nodes, which located along the drainage pathway that were included in the surgical field.[35](#cam41553-bib-0035){ref-type="ref"} The presence of lymph node invasion in imaging was defined as short axis \>1 cm, abnormal round morphology, heterogeneity shown in imaging, or central necrosis.[35](#cam41553-bib-0035){ref-type="ref"}

2.7. Propensity score matching {#cam41553-sec-0009}
------------------------------

To create 2 matching groups of patients with different combinations of treatment modality, a logistic regression model was built with the modality as the dependent variable and all other variables that could potentially influence its prognostic impact as independent variables. These variables were shown to correlate with survival after multivariate regression analysis.

2.8. Statistical analysis {#cam41553-sec-0010}
-------------------------

Baseline characteristics were summarized by descriptive statistics. Factors associated with determinations of multimodality were analyzed with Chi‐square test and its contingency coefficient (*C*). Potential factors predictive of OS and PFS were identified with univariate log‐rank comparisons and then multivariate proportional hazards regression model. Survival probability was estimated using Kaplan‐Meier statistics. Impacts of different treatment strategies on survival were evaluated with propensity score‐matched analysis. Two‐sided *P* values \<.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS version 22.0 (SPSS Inc., Armonk, NY).

3. RESULTS {#cam41553-sec-0011}
==========

3.1. Demographics {#cam41553-sec-0012}
-----------------

Four hundred and nineteen patients with LAPC were included. Demographic characteristics are outlined in Table [1](#cam41553-tbl-0001){ref-type="table"} in a detailed manner. Median follow‐up was 13 months (range: 5‐33 months). The median prescription dose and BED~10~ (biological effective dose, α/β=10) were 36 Gy (range: 30‐49.6 Gy) and 61.92 Gy (range: 48‐85.5 Gy) in 5‐8 fractions, respectively.

###### 

Baseline patient characteristics

  Characteristics                       Value
  ------------------------------------- -----------------------
  All patients                          419
  Sex                                   
  Male                                  250
  Female                                169
  Age (y)                               66 y (29‐90 y)
  ECOG PS                               
  0                                     120 (28.6%)
  1                                     216 (51.6%)
  2                                     83 (19.8%)
  Stage                                 
  IIA                                   76 (18.1%)
  IIB                                   210 (50.1%)
  III                                   133 (31.7%)
  Tumor locations                       
  Head                                  283 (67.5%)
  Body and tail                         136 (32.5%)
  Tumor diameter (cm)                   3.98 (2.4‐9.0)
  Baseline CA19‐9 (U/mL)                
  \<200                                 163 (38.9%)
  ≥200                                  256 (61.1%)
  Treatment sequence                    
  Nonchemotherapy                       33 (7.9%)
  Induction chemotherapy alone          45 (10.7%)
  Adjuvant chemotherapy alone           205 (48.9%)
  Induction and adjuvant chemotherapy   136 (32.5%)
  Prescription dose                     30‐49.6 Gy/5‐8f
  BED~10~                               61.92 Gy (48‐85.5 Gy)

BED~10~, biological effective dose, α/β=10.

John Wiley & Sons, Ltd

3.2. Factors correlated with determinations of different treatment modality {#cam41553-sec-0013}
---------------------------------------------------------------------------

Induction chemotherapy (including with or without adjuvant chemotherapy) was performed in 181 patients. A significant association was found only between baseline ECOG and induction chemotherapy (*C* = 0.582, *P* \< .001). Additionally, more patients with ECOG of 0 point (n = 119, 99.2%) had induction chemotherapy than those with ECOG of 1 or 2 points (n = 62, 20.7%; *P* \< .001). A total of 341 patients had adjuvant chemotherapy (including with or without induction chemotherapy). Tumor stage (*C* = 0.644, *P* \< .001), tumor diameter (*C* = 0.350, *P* \< .001), lymph node invasion (*C* = 0.467, *P* \< .001), and radiation‐induced toxicities within 2‐3 weeks after SBRT (*C* = 0.687, *P* \< .001) correlated with adjuvant chemotherapy. In details, adjuvant chemotherapy was performed more frequently in patients with stage III (n = 131, 98.5%; *P* \< .001) and lymph node invasion (n = 258, 97.0%; *P* \< .001) than those with stage II (n = 210, 73.4%) and noninvolvement of lymph nodes (n = 83, 54.2%). In addition, more patients with no radiation‐induced toxicities within 2‐3 weeks after SBRT (better performance status) underwent chemotherapy as scheduled (n = 273, 100%) than those with toxicities (n = 68, 46.6%; *P* \< .001).

3.3. Factors predictive of OS {#cam41553-sec-0014}
-----------------------------

Three hundred and sixty‐five patients died, while only 54 patients were still alive at the last follow‐up. The median OS was 13.2 months (95% CI: 12.8‐13.6 months). Furthermore, 1‐year and 2‐year OS rate was 63.0% and 13.6%, respectively. Before treatment, a level of CA19‐9 ≥ 200 U/mL was found in 257 patients, while 162 patients had a level \<200 U/mL. Among patients with a level of CA19‐9 ≥ 2 upper limit of normal, a significant decrease was found in 193 patients, while 134 patients had no response or even elevated levels of CA19‐9 after treatment. On the univariate analysis, age, different combinations of treatment modality, SIRI, CACI, CA19‐9 level, CA19‐9 response and BED~10~ were predictive of OS (Table [2](#cam41553-tbl-0002){ref-type="table"}). On multivariate regression, age, different combinations of treatment modality, CA19‐9 response and BED~10~ correlated with OS (Table [2](#cam41553-tbl-0002){ref-type="table"}).

###### 

Univariate and multivariate analysis of factors associated with OS

  Variable                              N = 419   Univariate, overall survival (mo)   *P* value (log‐rank)   Multivariate, hazard ratio   *P* value (Cox regression)                    
  ------------------------------------- --------- ----------------------------------- ---------------------- ---------------------------- ---------------------------- ------- -------- --------
  Age                                                                                                                                                                                   
  \<65                                  191       14.0                                13.3‐14.6              .021                         1                                             .025
  ≥65                                   228       12.8                                12.2‐13.4              1.29                         1.03‐1.62                    0.26             
  Smoking                                                                                                                                                                               
  Absent                                302       13.1                                12.5‐13.7              .564                         NS                           NS      NS       NS
  Present                               117       13.6                                12.8‐14.4              NS                           NS                           NS               
  Diabetes mellitus                                                                                                                                                                     
  Absent                                322       13.4                                13.0‐13.8              .320                         NS                           NS      NS       NS
  Present                               95        12.5                                11.9‐13.1              NS                           NS                           NS               
  VAS                                                                                                                                                                                   
  \<3                                   158       12.5                                11.5‐13.5              .455                         NS                           NS      NS       NS
  ≥3                                    261       13.5                                13.1‐13.9              NS                           NS                           NS               
  Weight loss                                                                                                                                                                           
  \<5 kg                                221       13.1                                12.4‐13.8              .306                         NS                           NS      NS       NS
  ≥5 kg                                 198       13.3                                12.8‐13.8              NS                           NS                           NS               
  Tumor diameter                                                                                                                                                                        
  \<4 cm                                227       13.2                                12.7‐13.6              .726                         NS                           NS      NS       NS
  ≥4 cm                                 192       13.2                                12.6‐13.8              NS                           NS                           NS               
  ECOG                                                                                                                                                                                  
  0                                     120       13.2                                11.7‐14.7              .159                         NS                           NS      NS       
  1                                     216       13.1                                12.4‐13.8              NS                           NS                           NS      NS       
  2                                     83        13.7                                12.7‐14.7              NS                           NS                           NS               
  Treatment modality                                                                                                                                                                    
  Nonchemotherapy                       33        11.2                                10.5‐11.8              \<.001                       1                                             \<.001
  Induction chemotherapy                45        12.2                                11.3‐13.0              0.60                         0.37‐0.99                    −0.51   .046     
  Adjuvant chemotherapy                 205       13.6                                13.0‐14.1              0.42                         0.28‐0.62                    −0.88   \<.001   
  Induction and adjuvant chemotherapy   136       13.3                                12.4‐14.2              0.50                         0.33‐0.76                    −0.69   .001     
  SIRI                                                                                                                                                                                  
  \<1.0                                 230       13.9                                13.3‐14.5              .012                         NS                           NS      NS       NS
  ≥1.0                                  189       12.4                                11.8‐13.0              NS                           NS                           NS               
  PNI                                                                                                                                                                                   
  \<48                                  223       13.1                                12.6‐13.6              .427                         NS                           NS      NS       NS
  ≥48                                   196       13.5                                12.6‐14.4              NS                           NS                           NS               
  CACI                                                                                                                                                                                  
  ≤4                                    236       13.8                                13.1‐14.5              .008                         NS                           NS      NS       NS
  \>4                                   183       12.5                                11.9‐13.1              NS                           NS                           NS               
  CA19‐9                                                                                                                                                                                
  \<200 U/mL                            163       13.9                                13.2‐14.6              .025                         NS                           NS      NS       NS
  ≥200 U/mL                             256       12.5                                11.9‐13.1              NS                           NS                           NS               
  CA19‐9 response                                                                                                                                                                       
  ≥74 U/mL with response                193       13.8                                13.1‐14.4              \<.001                       1                                             \<.001
  Remain \<74 U/mL                      92        14.8                                14.0‐15.6              0.80                         0.60‐1.06                    −0.23            
  ≥74 U/mL with no response             134       9.3                                 8.1‐10.4               2.88                         2.25‐3.70                    1.06             
  BED~10~                                                                                                                                                                               
  ≥60 Gy                                225       14.7                                14.3‐15.1              \<.001                       1                                             \<.001
  \<60 Gy                               194       10.8                                10.0‐11.5              2.59                         2.06‐3.26                    0.95             

VAS, visual analog scale; BED~10~, biological effective dose, α/β=10; SIRI, systemic inflammation response index; PNI, prognostic nutritional index; CACI, Charlson age‐comorbidity index; NS, nonsignificant.

John Wiley & Sons, Ltd

Additionally, the median OS of patients with nonchemotherapy, induction chemotherapy, adjuvant chemotherapy and induction and adjuvant chemotherapy was 11.2 months (95% CI: 10.5‐11.8 months), 12.2 months (95% CI: 11.3‐13.0 months), 13.6 months (95% CI: 13.0‐14.1 months), and 13.3 months (95% CI: 12.4‐14.2 months) (Figure [1](#cam41553-fig-0001){ref-type="fig"}A). Patients with induction chemotherapy, adjuvant chemotherapy, or induction and adjuvant chemotherapy all had a longer OS than patients without chemotherapy due to systemic disease or poor performance status (nonchemotherapy vs induction chemotherapy: *P* = .018; nonchemotherapy vs adjuvant chemotherapy: *P* \< .001; nonchemotherapy vs induction and adjuvant chemotherapy: *P* \< .001), while no significant difference was found between these three multimodality (induction chemotherapy vs adjuvant chemotherapy: *P* = .107; induction chemotherapy vs induction and adjuvant chemotherapy: *P* = .450; adjuvant chemotherapy vs induction and adjuvant chemotherapy: *P* = .240).

![OS (A) and PFS (B) of patients with different combinations of treatment modality](CAM4-7-2913-g001){#cam41553-fig-0001}

3.4. Factors predictive of PFS {#cam41553-sec-0015}
------------------------------

The median PFS was 8.2 months (95% CI: 7.9‐8.5 months), while 1‐year and 2‐year PFS rate was 21.5% and 14.1%, respectively. On univariate log‐rank comparisons, different combinations of treatment modality, CA19‐9 level, CA19‐9 response, and BED~10~ were associated with PFS (Table [3](#cam41553-tbl-0003){ref-type="table"}). On multivariate regression, a significant correlation was found between different combinations of treatment modality, CA19‐9 response, BED~10~, and PFS (Table [3](#cam41553-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analysis of factors associated with PFS

  Variable                              N = 419   Univariate, overall survival (mo)   *P* value (log‐rank)   Multivariate, hazard ratio   *P* value (Cox regression)                    
  ------------------------------------- --------- ----------------------------------- ---------------------- ---------------------------- ---------------------------- ------- -------- --------
  Age                                                                                                                                                                                   
  \<65                                  191       8.1                                 7.7‐8.5                .243                         NS                           NS      NS       NS
  ≥65                                   228       7.8                                 7.3‐8.3                NS                           NS                           NS               
  Smoking                                                                                                                                                                               
  Absent                                302       7.7                                 7.2‐8.1                .351                         NS                           NS      NS       NS
  Present                               117       8.4                                 8.0‐8.8                NS                           NS                           NS               
  Diabetes mellitus                                                                                                                                                                     
  Absent                                322       8.1                                 7.7‐8.5                .168                         NS                           NS      NS       NS
  Present                               95        7.7                                 7.0‐8.4                NS                           NS                           NS               
  VAS                                                                                                                                                                                   
  \<3                                   158       7.5                                 6.4‐8.5                .807                         NS                           NS      NS       NS
  ≥3                                    261       8.1                                 13.1‐13.9              NS                           NS                           NS               
  Weight loss                                                                                                                                                                           
  \<5 kg                                221       7.9                                 7.3‐8.5                .369                         NS                           NS      NS       NS
  ≥5 kg                                 198       7.9                                 7.5‐8.3                NS                           NS                           NS               
  Tumor diameter                                                                                                                                                                        
  \<4 cm                                227       8.1                                 7.6‐8.6                .269                         NS                           NS      NS       NS
  ≥4 cm                                 192       7.8                                 7.3‐8.2                NS                           NS                           NS               
  ECOG                                                                                                                                                                                  
  0                                     120       7.4                                 6.4‐8.4                .335                         NS                           NS      NS       
  1                                     216       7.9                                 7.5‐8.3                NS                           NS                           NS      NS       
  2                                     83        8.5                                 7.9‐9.1                NS                           NS                           NS               
  Treatment modality                                                                                                                                                                    
  Nonchemotherapy                       33        5.6                                 5.0‐6.2                \<.001                       1                                             \<.001
  Induction chemotherapy                45        6.4                                 6.0‐6.8                0.50                         0.31‐0.79                    −0.70   .003     
  Adjuvant chemotherapy                 205       8.6                                 8.2‐9.0                0.28                         0.19‐0.40                    −1.29   \<.001   
  Induction and adjuvant chemotherapy   136       8.1                                 7.4‐8.8                0.33                         0.22‐0.49                    −1.10   \<.001   
  SIRI                                                                                                                                                                                  
  \<1.0                                 230       8.2                                 13.3‐14.5              .077                         NS                           NS      NS       NS
  ≥1.0                                  189       7.6                                 11.8‐13.0              NS                           NS                           NS               
  PNI                                                                                                                                                                                   
  \<48                                  223       7.9                                 7.4‐8.4                .545                         NS                           NS      NS       NS
  ≥48                                   196       7.9                                 7.3‐8.5                NS                           NS                           NS               
  CACI                                                                                                                                                                                  
  ≤4                                    236       8.2                                 7.7‐8.7                .074                         NS                           NS      NS       NS
  \>4                                   183       7.8                                 7.3‐8.3                NS                           NS                           NS               
  CA19‐9                                                                                                                                                                                
  \<200 U/mL                            163       8.4                                 8.0‐8.8                .043                         NS                           NS      NS       NS
  ≥200 U/mL                             256       7.6                                 7.1‐8.1                NS                           NS                           NS               
  CA19‐9 response                                                                                                                                                                       
  ≥74 U/mL with response                193       8.5                                 8.1‐8.9                \<.001                       1                                             \<.001
  Remain \<74 U/mL                      92        9.5                                 8.4‐10.6               0.68                         0.53‐0.88                    −0.38            
  ≥74 U/mL with no response             134       5.6                                 5.0‐6.2                1.85                         1.47‐2.32                    0.61             
  BED~10~                                                                                                                                                                               
  ≥60 Gy                                225       9.8                                 9.1‐10.5               \<.001                       1                                             \<.001
  \<60 Gy                               194       6.2                                 5.7‐6.7                2.73                         2.22‐3.36                    1.00             

VAS, visual analogue scale; BED~10~, biological effective dose, α/β=10; SIRI, systemic inflammation response index; PNI, prognostic nutritional index; CACI, Charlson age‐comorbidity index; NS, nonsignificant.

John Wiley & Sons, Ltd

Furthermore, the median PFS of patients with nonchemotherapy, induction chemotherapy, adjuvant chemotherapy, and induction and adjuvant chemotherapy was 5.6 months (95% CI: 5.0‐6.2 months), 6.4 months (95% CI: 6.0‐6.8 months), 8.6 months (95% CI: 8.2‐9.0 months), and 8.1 months (95% CI: 7.4‐8.8 months) (Figure [1](#cam41553-fig-0001){ref-type="fig"}B). In details, longer PFS was found in patients with adjuvant chemotherapy and induction and adjuvant chemotherapy (nonchemotherapy vs induction chemotherapy: *P* = .070; nonchemotherapy vs adjuvant chemotherapy: *P* \< .001; nonchemotherapy vs induction and adjuvant chemotherapy: *P* \< .001) (induction chemotherapy vs adjuvant chemotherapy: *P* \< .001; induction chemotherapy vs induction and adjuvant chemotherapy: *P* = .034). Furthermore, it was indicated a marginal PFS benefit of adjuvant chemotherapy compared to induction and adjuvant chemotherapy (adjuvant chemotherapy vs induction and adjuvant chemotherapy: *P* = .048).

Though higher BED~10~ indicated better survival, there might be the potential impact of patients' performance status and tumor diameters on the decision of prescription dose. Hence, further analysis was performed. No significant difference was found between ECOG and radiation doses (Table [S1](#cam41553-sup-0001){ref-type="supplementary-material"}, *P* = .578) and between tumor diameters and prescription doses (Table [S2](#cam41553-sup-0001){ref-type="supplementary-material"}, *P* = .860).

3.5. Adjusted survival benefit of adjuvant chemotherapy and induction and adjuvant chemotherapy {#cam41553-sec-0016}
-----------------------------------------------------------------------------------------------

Regarding the survival benefit of adjuvant chemotherapy and induction and adjuvant chemotherapy, propensity score‐matched analysis was utilized for adjustment based on the previous factors predictive of OS and PFS. The median OS of patients with adjuvant chemotherapy and induction and adjuvant chemotherapy was 14.7 months (95% CI: 14.2‐15.2 months) and 13.1 months (95% CI: 12.3‐13.9 months) (*P* \< .001) (Figure [2](#cam41553-fig-0002){ref-type="fig"}A). The median PFS of patients receiving adjuvant chemotherapy and induction and adjuvant chemotherapy was 8.8 months (95% CI: 8.4‐9.2 months) and 8.1 months (95% CI: 7.4‐8.8 months) (*P* = .053) (Figure [2](#cam41553-fig-0002){ref-type="fig"}B).

![OS (A) and PFS (B) of patients with adjuvant and induction and adjuvant chemotherapy after adjustment](CAM4-7-2913-g002){#cam41553-fig-0002}

3.6. Tolerability of SBRT and chemotherapy {#cam41553-sec-0017}
------------------------------------------

Regarding acute radiation‐induced toxicity, 146 patients had grade 1‐2 abdominal pain or nausea and vomiting. There was no grade 3 or more acute radiation‐induced adverse effects. Only 1 patient experienced grade 3 late toxicity event of duodenitis. Additionally, among patients receiving induction chemotherapy, 4 patients (4/45, 8.9%) and 5 patients (5/45, 11.1%) had grade 3 neutropenia and abdominal pain or nausea, respectively. In terms of adjuvant chemotherapy, 24 patients (24/205, 11.7%) experienced grade 3 neutropenia or leukopenia, while grade 3 abdominal pain or nausea and vomiting were found in 21 patients (21/205, 10.2%).

4. DISCUSSION {#cam41553-sec-0018}
=============

Optimal treatment modality for LAPC still remained controversial. Although combinations of radiotherapy and chemotherapy or other targeted therapy have been employed in practice, best combinations of treatment regimens and durations have yet to be reached a consensus. Less emphasis was placed on treatment strategies, especially the combination of SBRT and chemotherapy for LAPC. Only the combination of conventional radiotherapy and chemotherapy were explored.

In the previous studies, concurrent chemoradiotherapy and chemotherapy have long been an issue. In GERCOR,[36](#cam41553-bib-0036){ref-type="ref"} patients initially received gemcitabine‐based chemotherapy and were randomly enrolled in following chemoradiotherapy and maintenance chemotherapy. The OS and PFS were longer in patients with chemotherapy followed by chemoradiotherapy. While in the LAP07,[9](#cam41553-bib-0009){ref-type="ref"} there was no significant difference in overall survival between these two modalities with similar regimens compared with the previous one, but chemoradiation has resulted in an increase in PFS. In a retrospective study, Huang et al[37](#cam41553-bib-0037){ref-type="ref"} also compared chemoradiotherapy with or without induction chemotherapy vs chemotherapy alone. Results were in favor of first‐line chemotherapy with following chemoradiotherapy. Nevertheless, intensive induction schedule of chemoradiotherapy with sequential chemotherapy was proved more toxic and less effective than chemotherapy alone.[12](#cam41553-bib-0012){ref-type="ref"} Hence, upfront chemotherapy followed by chemoradiotherapy may be a better option.

Although it was indicated that no significant difference in overall survival with chemoradiotherapy compared with chemotherapy alone in LAP07,[9](#cam41553-bib-0009){ref-type="ref"} this study only investigated the impacts of induction chemotherapy with concurrent chemoradiotherapy, and the technique of radiotherapy was three‐dimensional conformal radiation therapy. Therefore, the treatment strategy and prognostic values may be different when SBRT was substituted for conventional radiotherapy. In the present study, a major OS benefit was shown in patients with induction, or adjuvant and induction and adjuvant chemotherapy compared with those with nonchemotherapy, but no difference was found between these three strategies. Besides, adjuvant and induction and adjuvant chemotherapy increased PFS compared with induction chemotherapy and nonchemotherapy. In addition, it was implicated a probable better prognosis in adjuvant chemotherapy than induction and adjuvant chemotherapy after adjustment. The underlying reason might be attributable to a somewhat better abscopal effect produced by SBRT than conventional radiotherapy,[38](#cam41553-bib-0038){ref-type="ref"}, [39](#cam41553-bib-0039){ref-type="ref"} rendering a synergic effect of SBRT and chemotherapy. However, the abscopal effect was rarely found in clinical practice, which may be ascribed to two contradictory mechanisms of radiation‐induced immune response, namely subversion and reinstatement of immunosurveillance.[40](#cam41553-bib-0040){ref-type="ref"}

In our study, patients with lower ECOG tended to receive induction chemotherapy while stage III, lymph node involvement, and no radiation‐induced toxicity within 2‐3 weeks after SBRT correlated with the adjuvant chemotherapy. This might because patients with better performance status were more tolerant of chemotherapy and incidence of adverse effects of SBRT was probably lower than that of chemotherapy, which may indicate that upfront SBRT was more suitable for those with worse performance status. Additionally, more advanced stage required continuous intensive or consolidation chemotherapy after SBRT.

In our previous study, it was elucidated that patients receiving BED~10~ ≥60 Gy achieved better tumor response 6 months after SBRT though no correlation was found between the radiation dose and survival.[23](#cam41553-bib-0023){ref-type="ref"} However, it was shown in this study that BED~10~ ≥60 Gy associated with OS and PFS. Likewise, Krishnan et al[41](#cam41553-bib-0041){ref-type="ref"} also reported that BED~10~ \>70 Gy was the predictor of OS. The effect of higher dose on survival may be independent of the biases because the inclusion criteria were stringent and confounders were assessed. However, the possibility of influence of intangible factors could not be precluded. Therefore, this should be further validated. The limitation of the study was nonrandomization. Though it was commonly accepted that chemoradiotherapy was the standard modality for LAPC, which was consistent with the finding that chemoradiation improved survival compared with radiotherapy alone, a prospective randomized study on comparison of different treatment sequences was required.

Generally, induction and adjuvant chemotherapy, especially adjuvant chemotherapy, may be beneficial for patients with LAPC. Upfront combined regimens of SBRT and chemotherapy were probably dependent of baseline ECOG and tumor stage, lymph node invasion, and toxicity after SBRT, respectively.
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